The incidence of neovascular age-related macular degeneration (nAMD) is increasing worldwide [1]. The first-line treatment for nAMD typically involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents [2], administered following a Treat-and-Extend (TAE) regimen [3]. Here, VEGFA is linked to wet macular degeneration.